GE HealthCare

GE HealthCare (GEHC) declared a Q4 2025 cash dividend of $0.035 per share, payable February 13, 2026, to shareholders of record on January 9, 2026. This decision reflects the company’s commitment to shareholder value amidst increasing demand within the healthcare industry and technological advancements. GE HealthCare, a $19.7 billion global leader, focuses on medical technology, pharmaceutical diagnostics, and AI-enabled solutions. The company aims to optimize hospital efficiency and improve patient outcomes.

GE HealthCare’s CFO, Jay Saccaro, will present at the Jefferies Global Healthcare Conference on November 18, 2025. The presentation will cover GE HealthCare’s business strategy and growth opportunities amidst evolving healthcare market dynamics. Saccaro is expected to address the impact of a competitor’s FDA approval and reassure investors about GE HealthCare’s competitive position. He will likely highlight the company’s strengths, including global presence, diverse portfolio, and investments in AI and cloud technologies. A live webcast will be available on the GE HealthCare investor relations website.

At SNMMI, GE HealthCare unveils theranostics-enabling solutions focused on precision care. The debut of MIM Software’s LesionID Pro utilizes AI for automated pre-processing, streamlining workflows and aiding in personalized cancer treatment. Key highlights include the MINItrace Magni cyclotron, the Omni Legend PET/CT, and the StarGuide SPECT/CT, facilitating improved disease detection, treatment accuracy and efficient workflow. GE HealthCare aims to provide comprehensive solutions, from imaging to software, advancing personalized medicine and improving patient outcomes.